Showing results (141-150 of 188) with videos related to
Sort By:
Pageof 19
The Journal of Laboratory and Clinical Medicine|February 1, 1992
Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effectsS Saivin, M Petitou, J C Lormeau, et al.Journal of Thrombosis and Haemostasis : JTH|June 28, 2005
The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studiesP Gaussem, J-L Reny, C Thalamas, et al.Thrombosis Research|September 15, 1984
A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparationJ F Cade, M R Buchanan, B Boneu, et al.Thrombosis and Haemostasis|July 15, 1999
Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thiozyloside compoundP Masson, J Theveniaux, D Coup, et al.La Nouvelle Presse Medicale|February 14, 1976
[The half-life of iodine 131-labelled fibrinogen in cancer patients. Effects of heparin]A Boneu, J P Armand, A Blasco, et al.Thrombosis Research|October 15, 1988
Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological propertiesF Dol, C Caranobe, D Dupouy, et al.Scandinavian Journal of Clinical and Laboratory Investigation|February 1, 1987
Plasma fibrinolytic activity in a group of hypogonadic menA Bennet, P Sie, P Caron, et al.Thrombosis and Haemostasis|April 8, 1988
Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does notY Cadroy, F Dol, C Caranobe, et al.Thrombosis and Haemostasis|March 2, 1992
Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effectsS Saivin, M Petitou, J C Lormeau, et al.Thrombosis Research|June 1, 1992
Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbitS Saivin, F Dol, C Caranobe, et al.Pageof 19